Investigating the effectiveness of vitamin E drug in reducing the incidence of chronic neurotoxicity caused by oxaliplatin drug

Investigating the effectiveness of vitamin E in reducing the incidence of chronic neurotoxicity caused by oxaliplatin in patients with colon cancer undergoing adjuvant chemotherapy

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180313039085N3

Enrollment

Registered

2023-02-08

Start date

2023-03-21

Completion date

Unknown

Last updated

2023-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Drug-induced neurotoxicity. Drug-induced neurotoxicity

Interventions

Intervention 1: Intervention group: Oral vitamin E soft gelatin capsule with a dose of 400 international units, one daily for 180 days, is manufactured by Porateb Gostar Iranian pharmaceutical factory

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Colon cancer patients are candidates for adjuvant chemotherapy

Exclusion criteria

Exclusion criteria: Patients' unwillingness to participate in the study

Design outcomes

Primary

Measure	Time frame
Neurotoxicity. Timepoint: 1, 2, 3, 4, 5 and 6 months after the start of the study. Method of measurement: NCI-CTCAE-ver3 criterion.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactTayeb Ramim

Iran University of Medical Sciences

tayebramim@yahoo.com+98 21 6683 0007

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026